MILREM-ROBOTICS
30.6.2021 09:02:13 CEST | Business Wire | Press release
The consortium behind iMUGS, a 32,6 MEUR project with the aim of developing the European standard unmanned ground system (UGS), demonstrated the results of the first phase of the project – deploying unmanned systems to the battlefield and teaming them with manned units and vehicles. The demonstration was spearheaded by the coordinator of the consortium, Europe’s leading developer of robotics and autonomous systems Milrem Robotics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005046/en/
During iMUGS (integrated Modular Unmanned Ground System) a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems will be developed to standardize a European wide ecosystem for aerial and ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.
The system will utilize an existing unmanned ground vehicle – Milrem Robotics’ THeMIS – and a specific list of payloads.
"The main objective of the iMUGS project is to integrate robotic systems with existing manned technology into European defence forces adding a new capability that will overmatch our adversaries’ abilities," said Kuldar Väärsi, CEO of Milrem Robotics. He noted that iMUGS will contribute to the strategic autonomy of the European Union and strengthen the cooperation between the member states.
During the first demonstration consortium partners showcased how the THeMIS can be deployed onto the battlefield using common Armoured Personnel Carriers (APC) and teamed with unmanned aerial systems. Specific technology used were the Boxer APC by Krauss-Maffei Wegmann (KMW) and a tethered drone by Acecore Technologies. A multirotor drone by Atlas Dynamics was also part of the scenario.
Altogether two scenarios were played out in cooperation with the Estonian Defence Forces.
In the first scenario the THeMIS integrated with Acecore’s tethered drone was operated Beyond the Line of Sight (BLOS) by the soldiers and used to detect and target an enemy position. After determining the target indirect fire was ordered and after-action review performed using the drone footage.
The purpose of the second scenario was to retrieve a casualty from a crashed vehicle and afterwards retrieve the vehicle. Both actions were performed with the THeMIS UGV while the Boxer towed the UGV into the mission area and Atlas’ drone provided overwatch and situational awareness.
“The demonstration confirmed that we have the interaction between manned and unmanned systems, as well as the interaction of hardware and software, under control,” said Thomas Reining, iMUGS Project Manager in Krauss-Maffei Wegmann.
The requirements for the standardized UGS have been set by seven EU member states: Estonia, the leader of the project, and Belgium, Finland, France, Germany, Latvia, and Spain.
“All of the participating nations have shown great interest in contributing to the development of the European UGS,” said Martin Jõesaar, iMUGS project officer in the Estonian Centre for Defence Investments. “The countries understand that they have to grow with the industry to integrate this kind of new technology rapidly and guide the industry towards the best solutions.”
iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Talgen Cybersecurity, Safran Electronics & Defense, NEXTER Systems, Krauss-Maffei Wegmann, Diehl Defence, Bittium, Insta DefSec, (Un)Manned, dotOcean, Latvijas Mobilais Telefons, GMV Aerospace and Defence, and Royal Military Academy of Belgium.
Watch the Demo 1 Scenario 1 here - https://youtu.be/wAQHPdmm48M
Watch the Demo 1 Scenario 2 here - https://youtu.be/2vobuDOcfDA
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
